Abstract
Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Current Pharmaceutical Biotechnology
Title:Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Volume: 16 Issue: 5
Author(s): Tessalia D.L. Saraiva, Katia Morais, Vanessa B. Pereira, Marcela de Azevedo, Clarissa S. Rocha, Camila C. Prosperi, Ana C. Gomes-Santos, Luis Bermudez-Humaran, Ana M.C. Faria, Herve M. Blottiere, Philippe Langella, Anderson Miyoshi, Alejandra de Moreno de LeBlanc, Jean G. LeBlanc and Vasco Azevedo
Affiliation:
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Abstract: Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Export Options
About this article
Cite this article as:
Saraiva D.L. Tessalia, Morais Katia, Pereira B. Vanessa, Azevedo de Marcela, Rocha S. Clarissa, Prosperi C. Camila, Gomes-Santos C. Ana, Bermudez-Humaran Luis, Faria M.C. Ana, Blottiere M. Herve, Langella Philippe, Miyoshi Anderson, LeBlanc de Moreno de Alejandra, LeBlanc G. Jean and Azevedo Vasco, Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model, Current Pharmaceutical Biotechnology 2015; 16 (5) . https://dx.doi.org/10.2174/1389201015666141113123502
DOI https://dx.doi.org/10.2174/1389201015666141113123502 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin
Anti-Cancer Agents in Medicinal Chemistry Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Nanoemulsion Encapsulation and In Vitro SLN Models of Delivery for Cytotoxic Methotrexate
Current Drug Discovery Technologies Novel Insights Into c-Src
Current Pharmaceutical Design The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Editorial (Thematic Issue: Perspectives on Strategies for Overcoming Cancer Therapy Resistance)
Current Protein & Peptide Science microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression
Current Pharmaceutical Design Gender Differences in P-Glycoprotein Expression and Function: Effects on Drug Disposition and Outcome
Current Drug Metabolism Molecular Chaperone Activity and Biological Regulatory Actions of the TPR-Domain Immunophilins FKBP51 and FKBP52
Current Protein & Peptide Science VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Synthesis, Antimicrobial, Anticancer Evaluation and QSAR Studies of 3/4-Bromo Benzohydrazide Derivatives
Current Topics in Medicinal Chemistry QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres
Current Topics in Medicinal Chemistry Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets MicroRNA Regulatory Network in Human Colorectal Cancer
Mini-Reviews in Medicinal Chemistry Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Gut Epithelial Lining Makes the First Move
Current Immunology Reviews (Discontinued) Comparative Proteomic Analysis of Colon Cancer Cell HCT-15 in Response to All-Trans Retinoic Acid Treatment
Protein & Peptide Letters